Zaleplon vs Trazodone for Sleep: Dosing and Effectiveness

What trazodone is and why it gets used for sleep

Trazodone hydrochloride is a SARI antidepressant, chemically and mechanistically distinct from SSRIs, SNRIs, and the Z-drugs. The FDA approved it for major depressive disorder at doses generally in the 150 to 600 mg range. At those doses its sedating side effect was prominent enough that prescribers began using much smaller doses, 25 to 100 mg, specifically to treat insomnia. That sleep use has never gone through FDA review for a sleep indication. It remains off-label, and it has stayed common in practice because of its side-effect profile and non-controlled status rather than because of a large dedicated insomnia trial program.

Trazodone is not the same drug as trazodone's sedating cousins sold as sleep aids, nor is it a Z-drug or a benzodiazepine. It has no affinity for the GABA-A benzodiazepine binding site that zolpidem, eszopiclone, and zaleplon act on. Its sleep-promoting effect at low doses comes mainly from blocking histamine H1 receptors and alpha-1 adrenergic receptors, a pharmacology closer to a sedating antihistamine than to an SSRI. Because sleep doses occupy little of the serotonin transporter, trazodone at 50 mg does not treat depression on its own, and patients without depression can use it for insomnia without that mechanism being relevant.

The core, quotable answer for this page: trazodone is FDA-approved for depression and prescribed off-label for insomnia at 25 to 100 mg nightly; it is not a controlled substance and current evidence does not show a physical withdrawal syndrome at those doses, but the randomized-trial evidence specifically supporting it as a sleep treatment is thinner and older than the trial programs behind zolpidem and eszopiclone, so its guideline support is a weak recommendation rather than a strong one.

How it works at sleep doses versus at antidepressant doses

At 50 to 100 mg, sedation is driven primarily by H1 histamine antagonism and alpha-1 adrenergic blockade rather than by serotonergic activity. Small polysomnography studies from the 1990s reported that low-dose trazodone reduced wake time after sleep onset and increased slow-wave sleep in short trials, in contrast to the Z-drugs, which tend to leave slow-wave sleep unchanged or modestly suppressed. This is a plausible mechanistic explanation for why some patients report feeling more "recovered" on trazodone even at similar total sleep time, but it comes from small, older studies, and a reader should treat it as suggestive rather than established for the general insomnia population. Anyone relying on this distinction for a specific clinical decision should have the underlying study characteristics (sample size, population, dose, duration) confirmed against the primary literature before treating it as settled.

Trazodone does not bind GABA-A receptors, which is the pharmacologic reason it is not scheduled and does not produce the tolerance and withdrawal patterns seen with benzodiazepines and Z-drugs. Absence of a known dependence mechanism is not the same as an absence of any dependence in every patient; case-level exceptions are possible and are not systematically tracked.

Typical off-label dosing for insomnia

A common off-label starting dose is 50 mg taken about 30 minutes before bed, with 25 mg used as a lower starting point in older adults or in anyone sensitive to blood-pressure drops. Some clinicians titrate to 75 to 100 mg after one to two weeks if the lower dose is not effective. Above 100 mg for sleep alone, antidepressant-range side effects (and antidepressant-level serotonergic activity) become more likely without clear added sleep benefit, which is why higher doses are unusual when insomnia, not depression, is the target.

This article does not provide individualized dosing instructions. The dose, titration schedule, and duration of use should come from a prescriber who has reviewed the patient's full medication list, liver function, cardiac history, and reason for insomnia.

Populations that generally need dose adjustment or extra caution:

• Older adults: A lower starting dose is standard practice because of increased sensitivity to orthostatic hypotension and a longer effective half-life in this group.
• Hepatic impairment: Trazodone is hepatically metabolized; dose reduction is standard in moderate-to-severe liver disease, and the exact adjustment should come from a prescriber, not a general guide.
• CYP3A4 inhibitor use (for example, ketoconazole, ritonavir, clarithromycin): These can raise trazodone plasma levels meaningfully; concurrent use requires prescriber review, not self-adjustment.

Take trazodone with food or a light snack; taking it on an empty stomach raises peak plasma concentration and increases dizziness without improving sleep effect, consistent with general prescribing guidance for the drug (verify current label language against the FDA's Drugs@FDA database before treating specific administration instructions as current: https://www.accessdata.fda.gov/scripts/cder/daf/).

Trazodone versus zolpidem (Ambien)

Zolpidem is a Schedule IV controlled substance that acts as a positive allosteric modulator at GABA-A receptors and is FDA-approved specifically for short-term insomnia, with labeling that emphasizes using it for the shortest duration consistent with treatment goals. It carries an FDA boxed warning about complex sleep behaviors, including sleepwalking and sleep-driving, and the FDA lowered the recommended starting dose for women in 2013 because of higher next-morning blood levels of the active metabolite in women compared with men. Trazodone carries neither the boxed warning nor the sex-specific dosing requirement, and unlike zolpidem it is not a controlled substance, which matters for patients with a substance use history or for long-duration prescribing.

Reviews comparing the two drugs have reported similar reductions in subjective time to fall asleep, with less rebound insomnia reported after stopping trazodone than after stopping zolpidem, but the comparative trial base for this specific question is smaller than a reader might assume from how often the comparison is made in prescribing discussions; a precise effect-size comparison should not be quoted without checking the specific systematic review being cited. For insomnia expected to last more than four to six weeks, current guideline thinking favors starting with cognitive behavioral therapy for insomnia (CBT-I) rather than extended Z-drug use, which is part of why trazodone gets used as a longer-duration option when CBT-I has been tried, declined, or is not accessible.

Trazodone versus eszopiclone (Lunesta)

Eszopiclone is a Schedule IV Z-drug and is the only one FDA-approved without an explicit duration restriction, a distinction that reflects a longer-duration trial program at the time of approval, including a widely cited multi-month randomized trial in adults with chronic insomnia. Its most distinctive side effect is a metallic or bitter taste, reported by a meaningful minority of patients at the 3 mg dose, and its label includes a caution about impaired driving ability the morning after dosing.

Trazodone has not been studied for insomnia in a trial of comparable size, duration, or FDA-review rigor to eszopiclone's pivotal program. That is a genuine evidence gap, not a minor caveat: clinicians who choose trazodone over eszopiclone for long-term use are trading a stronger trial base for a non-controlled substance and (based on available reports) a lower dependence risk, not choosing the option with more direct proof of long-term efficacy. Readers should not assume trazodone and eszopiclone have been shown to work equally well; they have been evaluated with very different depth of evidence.

Trazodone versus zaleplon (Sonata)

Zaleplon has the shortest half-life of the commonly used Z-drugs, roughly an hour, and is FDA-approved for sleep-onset insomnia. Because of that short half-life it can be taken in the middle of the night if at least four hours of sleep opportunity remain, but it does little for people whose main problem is staying asleep rather than falling asleep. Trazodone's longer half-life, roughly 5 to 9 hours, makes it more plausible as an option for sleep-maintenance problems, but there is no well-established head-to-head trial directly comparing trazodone and zaleplon for insomnia, so this remains a reasoning-based comparison rather than a trial-proven one.

Trazodone versus melatonin

Melatonin is an over-the-counter hormone supplement, not a prescription drug, and it works through a different pathway: it signals circadian phase rather than producing direct sedation. Meta-analytic data on melatonin generally show a modest reduction in time to fall asleep, on the order of several minutes rather than tens of minutes, and melatonin's clearest evidence base is in circadian-rhythm problems such as jet lag and delayed sleep phase rather than in primary chronic insomnia. The American Academy of Sleep Medicine's 2017 clinical practice guideline reportedly recommends against using melatonin as a treatment for sleep-onset or sleep-maintenance chronic insomnia in adults; this specific recommendation should be checked against the current published guideline before being restated as a direct quotation, since the original guideline language was not independently verified for this draft.

Compared with melatonin, trazodone's available polysomnography and small trial data suggest a larger effect on both falling asleep and staying asleep for people with a diagnosed insomnia disorder, though again from a thinner trial base than the Z-drugs. Melatonin's real advantages are accessibility, low cost, and an established safety record at typical over-the-counter doses; for mild sleep difficulty, jet lag, or shift-work-related circadian misalignment, it remains a reasonable first step before moving to a prescription option.

A note on newer alternatives

Dual orexin receptor antagonists such as lemborexant and suvorexant represent a newer FDA-approved drug class for insomnia that this article's original source material did not address. A 2021 network meta-analysis compared lemborexant with other insomnia treatments and is a relevant primary source for anyone weighing trazodone against orexin antagonists, though the specific comparative numbers from that analysis should be pulled directly from the paper rather than summarized secondhand here: https://pubmed.ncbi.nlm.nih.gov/34121443/. This page focuses on trazodone versus zolpidem, eszopiclone, zaleplon, and melatonin; a reader specifically choosing between trazodone and an orexin antagonist should ask a prescriber for that comparison directly.

Side effects and safety

Commonly reported side effects at 50 to 100 mg include daytime drowsiness, orthostatic hypotension and dizziness (most pronounced in the first week and when taken without food), dry mouth, and blurred vision. Reported incidence figures vary across sources and study populations, so specific percentages should be confirmed with a prescriber rather than treated as fixed.

Rare but serious risks include:

• Priapism, a prolonged and painful erection that is a urologic emergency if it lasts more than two hours. This is a recognized rare risk of trazodone; exact incidence estimates vary between sources and should be verified rather than quoted as a precise rate. Men with a history of priapism, sickle cell disease, or anatomical penile conditions, and men taking phosphodiesterase-5 inhibitors, need individualized risk discussion before starting trazodone.
• QT interval prolongation, which is dose-dependent. At typical sleep doses, meaningful QT prolongation appears uncommon in people without underlying cardiac disease, but combining trazodone with other QT-prolonging drugs (certain antipsychotics, certain antibiotics) warrants ECG monitoring on a prescriber's judgment.
• Serotonin syndrome, rare at sleep doses but possible with MAOIs, linezolid, methylene blue, or high-dose serotonergic antidepressants. This combination should be avoided or managed only under direct medical supervision.
• Falls in older adults. Observational pharmacovigilance data have linked trazodone use to increased fall reporting in older adults, consistent with its sedative and blood-pressure-lowering effects. This supports starting at a lower dose and reassessing regularly in this age group, though a specific numeric risk ratio should be confirmed against the primary study before being cited as an exact figure.

Who is, and is not, a reasonable candidate

Trazodone tends to fit patients who:

• Have chronic insomnia and have completed or explicitly declined CBT-I
• Need pharmacotherapy for longer than the four-to-six-week window typically recommended for Z-drugs
• Have a substance use history that makes a Schedule IV medication undesirable
• Have comorbid depression or anxiety where a low-dose sedating agent might reasonably address sleep alongside other symptoms, under a prescriber's judgment
• Take a stimulating antidepressant (for example, bupropion or fluoxetine) and need help with drug-induced insomnia

Trazodone is a poor fit for patients who:

• Are male with a history of priapism or certain anatomical penile conditions
• Are taking an MAOI or linezolid
• Have uncontrolled QT prolongation or are on multiple other QT-prolonging drugs
• Are pregnant, particularly in the first trimester, where safety data are limited and a prescriber's individualized assessment is required

None of this substitutes for an individualized medical evaluation. Anyone experiencing an erection lasting more than two hours, chest pain, fainting, or signs of serotonin syndrome (agitation, high fever, muscle rigidity, rapid heart rate) needs urgent medical care, not a wait-and-see approach.

What is established, what is plausible, and what is not established

Established: Trazodone is FDA-approved for major depressive disorder, not for insomnia. It is not a controlled substance. Its main sleep-dose mechanism is H1 and alpha-1 receptor blockade rather than serotonin reuptake inhibition. Priapism and QT prolongation are recognized, described risks of the drug class and dose range, even though precise incidence numbers vary by source and should be verified before being cited exactly.

Plausible but not firmly established at scale: That trazodone increases slow-wave sleep more than Z-drugs do, based on small older polysomnography studies rather than large modern trials. That trazodone produces less rebound insomnia than zolpidem on discontinuation, based on limited comparative literature. That trazodone is broadly non-habit-forming in every patient; the absence of a known pharmacologic dependence mechanism is not the same as a guarantee of no dependence in all individuals.

Not established: A head-to-head trial proving trazodone is as effective as eszopiclone or zolpidem for chronic insomnia over many months. A validated numeric comparison of trazodone against melatonin or zaleplon from a matched trial. Long-term (multi-year) safety data for nightly trazodone use for insomnia specifically, as opposed to depression-dose data.

A decision framework for choosing among trazodone, a Z-drug, and melatonin

This is a structured way to think through the tradeoffs; it is not a substitute for a prescriber's individualized assessment, and it does not set a dose.

1. Identify the insomnia pattern.

• Trouble falling asleep only, with a plausible circadian trigger (travel, shift work): melatonin is a reasonable low-risk first step.
• Trouble falling asleep only, no circadian trigger, short expected duration (days to a few weeks): a short-acting Z-drug such as zaleplon may fit better than trazodone because trazodone's longer half-life offers no advantage for onset-only insomnia.
• Trouble staying asleep, or both falling asleep and staying asleep: trazodone or eszopiclone are more plausible fits than zaleplon because of longer half-life coverage through the night.

2. Screen for hard exclusions before considering trazodone.

• Current MAOI or linezolid use: rules out trazodone.
• History of priapism, sickle cell disease, or PDE5-inhibitor use in men: requires an explicit risk discussion before trazodone, not a default choice.
• Uncontrolled QT prolongation or multiple other QT-prolonging drugs: requires cardiology input before trazodone.

3. Weigh duration of expected need against controlled-substance status.

• Expected use under four to six weeks, no substance use history, no exclusion above: a Z-drug (zolpidem or eszopiclone) has a stronger dedicated trial base for this exact use case.
• Expected use beyond six weeks, a substance use history, or a strong preference to avoid a scheduled medication: trazodone becomes a reasonable discussion point specifically because of its non-controlled status, with the explicit understanding that its own insomnia trial base is thinner than the Z-drug it is replacing.

4. Build in reassessment regardless of which drug is chosen.

• Reassess at four weeks: is the medication still needed, and is CBT-I now accessible?
• Reassess again at twelve weeks and at least annually thereafter, more frequently in patients over 65, given fall and cognitive-impairment concerns associated with sedative-hypnotics generally.
• At any reassessment, a trial taper or a structured CBT-I course should be offered rather than indefinite renewal without discussion.

5. Escalate to urgent care, not to a dose change, if: an erection lasts more than two hours, there are signs of serotonin syndrome, fainting or a new irregular heartbeat occurs, or sedation is severe enough to impair safe function the next day.

Drug interactions worth flagging to a prescriber

Trazodone is metabolized mainly through CYP3A4. Inhibitors of that enzyme (for example, ketoconazole, itraconazole, ritonavir, clarithromycin) can raise trazodone levels; inducers (for example, rifampin, carbamazepine, phenytoin, St. John's Wort) can lower them. Alcohol, benzodiazepines, opioids, and other sedating antihistamines add to trazodone's sedative effect and should generally not be combined without medical guidance. Trazodone may raise digoxin and phenytoin levels in some patients, which is a reason to disclose all current medications before starting it rather than to adjust anything independently.

Stopping trazodone

Available evidence does not show a classic physical withdrawal syndrome after stopping trazodone at hypnotic doses, and a taper is not generally required after short-term use the way it is for benzodiazepines. Some patients who have used higher doses nightly for months report a brief return of insomnia symptoms for a few nights after stopping; this is better understood as the underlying insomnia reasserting itself than as a drug withdrawal effect, though the distinction is not always easy to make in an individual patient. Long-term use of any sedative-hypnotic in older adults has been associated in the literature with falls, cognitive effects, and motor vehicle accidents, which is why annual reassessment of the ongoing need for the medication is standard practice in this age group, and reasonable practice at any age.

Evidence gaps a reader should know about

This draft is built primarily on general pharmacology, FDA label concepts, and a network meta-analysis on lemborexant identified as a verified primary source. Several specific numeric claims that commonly circulate about trazodone (exact priapism incidence, exact fall-risk ratios, exact melatonin sleep-onset-latency reduction, specific SLEEP-1 trial numbers) could not be independently verified against a confirmed primary source for this draft and have been described qualitatively rather than with fabricated precision. A clinical reviewer with direct access to the primary trial literature and the current FDA label should confirm any number before it is published with a specific citation.